[Clinical efficacy of combined anti-Helicobacter treatment of patients with duodenal ulcer].

Abstract

84 patients with duodenal ulcer and positive by Helicobacter pylori (HP) were divided into two groups. Group 1 consisted of 42 patients who received omeprasol, metranidasol and clarithromycin. Group 2 of 42 patients received rovamycin instead of clarythromycin. The results of the study show that anti-HP regimen with rovamycin is superior to clarythromycin by main criteria (percent of healed ulcers, HP eradication, time to remission, recurrence rate, side effects rate). Thus, three-component therapy of patients with recurrent duodenal ulcer maintains intragastric acidity optimal for fast healing of ulcer defect.

• Authors: N V Kirika, N I Bodrug, S I Butorov, O N Verbitskiĭ, A Iu Ridlovskiĭ, I V Butorov, D I Lagutkin, L I Martyniuk
• Journal: Klinicheskaia meditsina (Klin Med (Mosk)) Vol. 81 Issue 1 Pg. 37-9 ( 2003) ISSN: 0023-2149 [Print] Russia (Federation)
• Vernacular Title: Klinicheskaia effektivnost' kombinirovannogo antikhelikobakternogo lecheniia bol'nykh iazvennoĭ bolezn'iu dvenadtsatiperstnoĭ kishki.
• PMID: 12650094 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Anti-Ulcer Agents
• Spiramycin
• Clarithromycin
• Omeprazole

Topics

• Adult
• Anti-Bacterial Agents (therapeutic use)
• Anti-Ulcer Agents (therapeutic use)
• Clarithromycin (therapeutic use)
• Drug Therapy, Combination
• Duodenal Ulcer (drug therapy, microbiology)
• Female
• Helicobacter pylori (drug effects)
• Humans
• Male
• Middle Aged
• Omeprazole (therapeutic use)
• Spiramycin (therapeutic use)
• Treatment Outcome